{"title":"Biotech news from around the world","authors":"","doi":"10.1038/s41587-025-02643-7","DOIUrl":null,"url":null,"abstract":"<p>Amgen invests $200 million in a new technology center in southern India and plans to invest further in the future to strengthen its operations and R&D capabilities. The site in Hyderabad currently employs 300 people, with plans for 1,700 more recruits skilled in data analytics, AI and digital health technologies.</p><p>The Canadian government cancels a deal with US-based Novavax to buy millions of doses of a COVID-19 vaccine that was to be made in a new biologics manufacturing facility in Montreal. It would have been the first to be produced in Canada. Novavax says the cause is the company not receiving regulatory approval by the end of 2024 for its COVID-19 vaccine using bulk antigen produced at the facility.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"61 1","pages":""},"PeriodicalIF":33.1000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1038/s41587-025-02643-7","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Amgen invests $200 million in a new technology center in southern India and plans to invest further in the future to strengthen its operations and R&D capabilities. The site in Hyderabad currently employs 300 people, with plans for 1,700 more recruits skilled in data analytics, AI and digital health technologies.
The Canadian government cancels a deal with US-based Novavax to buy millions of doses of a COVID-19 vaccine that was to be made in a new biologics manufacturing facility in Montreal. It would have been the first to be produced in Canada. Novavax says the cause is the company not receiving regulatory approval by the end of 2024 for its COVID-19 vaccine using bulk antigen produced at the facility.
期刊介绍:
Nature Biotechnology is a monthly journal that focuses on the science and business of biotechnology. It covers a wide range of topics including technology/methodology advancements in the biological, biomedical, agricultural, and environmental sciences. The journal also explores the commercial, political, ethical, legal, and societal aspects of this research.
The journal serves researchers by providing peer-reviewed research papers in the field of biotechnology. It also serves the business community by delivering news about research developments. This approach ensures that both the scientific and business communities are well-informed and able to stay up-to-date on the latest advancements and opportunities in the field.
Some key areas of interest in which the journal actively seeks research papers include molecular engineering of nucleic acids and proteins, molecular therapy, large-scale biology, computational biology, regenerative medicine, imaging technology, analytical biotechnology, applied immunology, food and agricultural biotechnology, and environmental biotechnology.
In summary, Nature Biotechnology is a comprehensive journal that covers both the scientific and business aspects of biotechnology. It strives to provide researchers with valuable research papers and news while also delivering important scientific advancements to the business community.